Medline IPO Becomes the Largest Global Listing of 2025

Medline completed its IPO on December 17, 2025. The company raised $6.26 billion in the offering. The sale took place on the Nasdaq in New York. This was the largest IPO of the year. The main keyword is “Medline IPO.”

The deal drew wide attention because the market has been slow in 2025. According to Reuters, the offering exceeded all other listings worldwide. It also showed that investors still want stable firms with steady cash flow. Medline fit that demand well.

Medline IPO Drives Strong Investor Demand

The Medline IPO priced at $29 per share. The company sold more than 216 million shares. Underwriters may buy more shares through a greenshoe option. Reuters said this may add extra stability in early trading.

Medline plans to use most funds to cut debt. The company held about $16.8 billion in debt before the IPO. Much of it came from the 2021 private‑equity buyout by Blackstone, Carlyle, and Hellman & Friedman. The firm said lower debt will help long‑term growth.

The company sells over 335,000 medical products. It serves hospitals, clinics, and care centers around the world. It also runs 69 distribution sites in the United States. Medline says it can reach 95% of U.S. customers in one day. This reach is part of its value to investors.

Reuters reported that Medline made $20.6 billion in sales in the first nine months of 2025. Net income reached $977 million. These results showed strong demand from the health sector. It also showed stable growth in a slow market year.

How the Medline IPO May Shape Healthcare and Markets

The Medline IPO may influence other firms planning to list in 2026. Many private‑equity groups are watching closely. They want to know if large industrial firms can attract strong demand. Early signs point to yes.

But Medline also faces new pressure. The company said tariffs may cut 2026 income by up to $200 million. This number raised some concern. Still, Medline believes scale and supply reach will help absorb cost hits.

Analysts say the Medline IPO could open the door for other major listings next year. It may help push firms waiting on the sidelines. A strong performance would build confidence across the market.

The Medline IPO now stands as the key market event of late 2025. Investors will watch how Medline uses its funds and cuts debt. The success of the Medline IPO could influence the pace of large U.S. listings in 2026.

FYI (keeping you in the loop)-

Q1: What is the Medline IPO?

The Medline IPO is the company’s public listing on Nasdaq. It raised $6.26 billion. It was the largest global IPO of 2025.

Q2: Why was the Medline IPO important?

It showed strong demand for stable firms. It also signaled a return of large IPOs. Reuters said it topped all other 2025 listings.

Q3: How did Medline perform before the IPO?

The company made $20.6 billion in sales in the first nine months of 2025. Net income reached $977 million. Reuters called the results stable.

Q4: What risks does Medline face after the IPO?

The company expects tariffs to reduce income next year. Debt remains high even after repayment. Investors will watch margin pressure.

Q5: How will IPO funds be used?

Most funds will reduce debt. Some will support liquidity for older owners. This was confirmed by Reuters reports.